As of 2025-06-03, the EV/EBITDA ratio of Suven Life Sciences Ltd (SUVEN.NS) is -36.78. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SUVEN.NS's latest enterprise value is 52,753.26 mil INR. SUVEN.NS's TTM EBITDA according to its financial statements is -1,434.45 mil INR. Dividing these 2 quantities gives us the above SUVEN.NS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 20.9x | 17.6x |
| Forward P/E multiples | 11.6x - 24.4x | 17.5x |
| Fair Price | (81.41) - (133.38) | (111.54) |
| Upside | -133.1% - -154.2% | -145.3% |
| Date | EV/EBITDA |
| 2025-06-02 | -36.78 |
| 2025-05-30 | -36.03 |
| 2025-05-29 | -34.85 |
| 2025-05-28 | -36.44 |
| 2025-05-27 | -35.16 |
| 2025-05-26 | -31.97 |
| 2025-05-23 | -30.89 |
| 2025-05-22 | -31.93 |
| 2025-05-21 | -31.50 |
| 2025-05-20 | -30.67 |
| 2025-05-19 | -31.00 |
| 2025-05-16 | -28.09 |
| 2025-05-15 | -27.39 |
| 2025-05-14 | -27.20 |
| 2025-05-13 | -25.43 |
| 2025-05-12 | -22.67 |
| 2025-05-09 | -20.95 |
| 2025-05-08 | -20.21 |
| 2025-05-07 | -20.19 |
| 2025-05-06 | -18.73 |
| 2025-05-05 | -19.35 |
| 2025-05-02 | -18.04 |
| 2025-04-30 | -18.81 |
| 2025-04-29 | -19.16 |
| 2025-04-28 | -19.71 |
| 2025-04-25 | -19.86 |
| 2025-04-24 | -20.90 |
| 2025-04-23 | -19.18 |
| 2025-04-22 | -18.96 |
| 2025-04-21 | -18.76 |
| 2025-04-17 | -18.51 |
| 2025-04-16 | -18.66 |
| 2025-04-15 | -18.67 |
| 2025-04-11 | -18.03 |
| 2025-04-09 | -17.67 |
| 2025-04-08 | -17.83 |
| 2025-04-07 | -17.45 |
| 2025-04-04 | -18.92 |
| 2025-04-03 | -19.34 |
| 2025-04-02 | -18.39 |
| 2025-04-01 | -17.91 |
| 2025-03-28 | -16.79 |
| 2025-03-27 | -16.82 |
| 2025-03-26 | -17.35 |
| 2025-03-25 | -17.46 |
| 2025-03-24 | -18.26 |
| 2025-03-21 | -18.29 |
| 2025-03-20 | -18.51 |
| 2025-03-19 | -18.28 |
| 2025-03-18 | -17.34 |